BioSpace News Archive

Olympus among other core businesses, announced today the expansion of its EndoTherapy product line, building on the company’s commitment to innovation and advancement in the field of endoscopy and its history as a pioneer in Endoscopic Submucosal Dissection (ESD).

CASI Pharma announced that it has entered into definitive agreements with certain institutional and accredited investors.

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for Faslodex (fulvestrant).

Eleven Biotherapeutics announced the appointment of Richard F. Fitzgerald as Interim CFO, effective October 20, 2017.

Aerie Pharmaceuticals, Inc today announced that, in their review of Aerie product candidate RhopressaTM (netarsudil ophthalmic solution) 0.02%.

Tauriga Sciences, Inc. today announced that it has fully retired the original face value of $96,000 USD 12.00% convertible debenture issued by the Company to Group 10 Holdings, LLC on July 14, 2015.

Endonovo Receives Positive Results from Pre-Clinical Study of Non-Invasive Electroceutical Non-Invasive Electroceutical Significantly Increased Cardiac Function and Reduced Ventricular Remodeling in Infarcted Animals LOS ANGELES, CA -- (Marketwired) -- Oct 13, 2017 -- Endonovo Therapeutics, Inc. ( OTCQB : ENDV ) (“Endonovo” or the “Company”), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today report

Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb